| 序号 |
标题 |
次数 |
作者 |
发布时间 |
| 62731 |
低分子量CLT1肽靶向Gd(III)螯合物CLT1-dL-(Gd-DOTA) |
141 |
h |
2024-12-19 |
| 62732 |
DOTA-1,2-二硬脂酰-sn-甘油-3-磷酸乙醇胺脂质 |
132 |
h |
2024-12-19 |
| 62733 |
1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA17,19) |
96 |
h |
2024-12-19 |
| 62734 |
cas:1061569-06-9，4-formyl-N-(2-(2-hydroxyethoxy)ethyl)benzamide ADC抗体偶联药物 |
71 |
zyl |
2024-12-19 |
| 62735 |
DBCO-PEG4-VA-PBD，2241644-09-5，ADC定制 |
68 |
wyh |
2024-12-19 |
| 62736 |
Val-Cit-PAB-MMAE，cas:644981-35-1，ADC定制 |
69 |
wyh |
2024-12-19 |
| 62737 |
DOTA-GMSH 1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)偶联α-黑素细胞刺激素(α-MSH)类似物 |
94 |
h |
2024-12-19 |
| 62738 |
mDPR-Val-Cit-PAB-MMAE，1491152-26-1，ADC定制 |
70 |
wyh |
2024-12-19 |
| 62739 |
G3-(Gd-DTPA)(24)DOTA-钆(Gd)大分子造影剂 |
152 |
h |
2024-12-19 |
| 62740 |
DOTA-多柔比星 DOTA-DOX |
97 |
h |
2024-12-19 |
| 62741 |
聚(HPMA)-c(RGDyK)-DOTA |
53 |
h |
2024-12-19 |
| 62742 |
1,4,7,10-四氮杂环十二烷-1,4,7,10-四乙酸(DOTA)螯合剂共轭的应变环辛烯衍生物二苄基环辛烯(DBCO) |
74 |
h |
2024-12-19 |
| 62743 |
PDDEC-NB；2-methyl-2-(pyridin-2-yldisulfanyl)propyl 4-nitrophenyl carbonate |
69 |
zyl |
2024-12-19 |
| 62744 |
(67)Ga-DOTA复合物共轭二膦酸盐(67)Ga-DOTA-Bn-SCN-HBP |
102 |
h |
2024-12-19 |
| 62745 |
MWCNT/PEI-FI-DOTA(Gd)-PEG 异硫氰酸荧光素(FI)和钆(Gd)螯合剂共价接枝聚乙烯亚胺修饰的多壁碳纳米管 |
113 |
h |
2024-12-19 |
| 62746 |
DOTA-Cys-hAb47 螯合剂DOTA偶联半胱氨酸-抗EphB4抗体hAb47和hAb131 |
144 |
h |
2024-12-19 |
| 62747 |
1,4,7,10-四氮杂环十二烷-N,N,N,N-四乙酸(DOTA)-F(ab)2-曲妥珠单抗 |
73 |
h |
2024-12-19 |
| 62748 |
DOTA-MG11(DOTA-DGlu-Ala-Tyr-Gly-Trp-Met-Asp)DOTA肽缀合物 |
90 |
h |
2024-12-19 |
| 62749 |
AcLys-PABC-VC-Aur0101， cas:1438851-17-2，ADC定制 |
119 |
wyh |
2024-12-19 |
| 62750 |
cas:107348-47-0，2,5-dioxopyrrolidin-1-yl 3-(pyridin-2-yldisulfanyl)butanoate ADC抗体偶联药物 |
62 |
zyl |
2024-12-19 |
| 62751 |
SMCC-DM4 ， cas:1228105-52-9，ADC定制 |
58 |
wyh |
2024-12-19 |
| 62752 |
cas:1639939-40-4 Mal-Val-Ala-PAB-PNP |
68 |
zyl |
2024-12-19 |
| 62753 |
MA-PEG8-VA-PAB-SG3199，ADC定制 |
82 |
wyh |
2024-12-19 |
| 62754 |
Acid-PEG4-Val-Cit-PAB-MMAE |
57 |
zyl |
2024-12-19 |
| 62755 |
MC-Val-Cit-PAB-Indibulin，cas:2055896-95-0，ADC定制 |
76 |
wyh |
2024-12-19 |
| 62756 |
cas:1096584-62-1 Mal-Val-Cit-PAB-PNP |
75 |
zyl |
2024-12-19 |
| 62757 |
cas:863971-53-3 Fmoc-Val-Cit-PAB-PNP |
73 |
zyl |
2024-12-19 |
| 62758 |
MC-Sq-Cit-PAB-Dolastatin10 ，cas:1941168-65-5，ADC定制 |
87 |
wyh |
2024-12-19 |
| 62759 |
Mal-PEG2-Val-Cit-PAB-OH ADC抗体偶联药物 |
73 |
zyl |
2024-12-19 |
| 62760 |
N3-PEG4-DYKDDDD-Doxorubicin，ADC定制 |
91 |
wyh |
2024-12-19 |
| 62761 |
MA-vc-PAB-DM1 cas:1464051-44-2 |
62 |
zyl |
2024-12-19 |
| 62762 |
DBCO-PEG4-VC-PAB-DMAE-Duocarmycin SA |
82 |
zyl |
2024-12-19 |
| 62763 |
VC-PAB-DMAE-PNU159682 ADC抗体偶联药物 |
79 |
zyl |
2024-12-19 |
| 62764 |
MC-GGFG-DX8951 cas:1600418-29-8 |
70 |
zyl |
2024-12-19 |
| 62765 |
DOTA-NGR NGR肽偶联1,4,7,10-四氮杂环十二烷-N,N’,N”,N”’-四乙酸(DOTA) |
78 |
h |
2024-12-19 |
| 62766 |
N3-PEG4-vc-PAB-Doxorubicin 叠氮PEG修饰维生素C-阿霉素的介绍 |
170 |
zyl |
2024-12-19 |
| 62767 |
DOTA-Ahx-(d-Lys6-GnRH1)DOTA偶联的d-Lys6-GnRH肽 |
82 |
h |
2024-12-19 |
| 62768 |
DOTA-porphyrin 双功能螯合剂DOTA偶联5-(对-氨基-丙烯-氧苯基)-10,15,20-三-(对-羧基-甲基-烯-氧苯基)卟啉 |
110 |
h |
2024-12-19 |
| 62769 |
VC-SECO DUBA analogue，ADC定制 |
82 |
wyh |
2024-12-19 |
| 62770 |
DOTA-H-Lys(Boc)-OH-SWCNTs 赖氨酸胺手柄功能化的单壁碳纳米管偶联DOTA螯合剂 |
76 |
h |
2024-12-19 |
| 62771 |
[DOTA-A1]-ZHER2:S1 抗HER2 ZHER2:S1亲和体分子缀合DOTA |
99 |
h |
2024-12-19 |
| 62772 |
Vc-MMAD cas:1401963-17-4的结构式 |
67 |
zyl |
2024-12-19 |
| 62773 |
DOTA-E(c(RGDfK))大环DOTA偶联双环肽E[c(RGDfK)] |
88 |
h |
2024-12-19 |
| 62774 |
CL2A-SN38，cas:1279680-68-0，ADC定制 |
147 |
wyh |
2024-12-19 |
| 62775 |
DOTA-gluBBN DOTA缀合铃蟾肽类似物 |
64 |
h |
2024-12-19 |
齐岳微信公众号
官方微信
库存查询